Nurix Therapeutics Inc (NAS:NRIX)
$ 15.11 -0.79 (-4.97%) Market Cap: 922.73 Mil Enterprise Value: 753.69 Mil PE Ratio: 0 PB Ratio: 4.41 GF Score: 67/100

Nurix Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 04:25PM GMT
Release Date Price: $12.98 (-0.38%)
Rich Law
Credit Suisse Group - Analyst

Hey, let's get going. Good afternoon. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our next session with Nurix and joining us will be Arthur Sands, President and CEO; and Hans van Houte, CFO. And I think we're going to kick it off with a presentation from you guys. And we'll kick it off on that.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO, and Board Director

That is correct. Thank you very much, Rich. Let me just stand up so I can look at the big screen too. We will be making certain forward-looking statements so I refer you to our filings with the SEC regarding the risk factors that face our business.

So Nurix, we're a small molecule drug discovery company, we're not oncology. We have four programs in clinical development.

At the center of our drug discovery system at Nurix is the E3 ligase which is pictured here in the center of the screen. It's an enzyme complex system. There are over 600 E3 ligases encoded in the human genome, and these control all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot